Clinical trial NCT06750523: Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention
Official title: Getting Bone Health Right From the Start: Innovative Technology and New Mechanims of Mother-fetus Cross Talk for Osteopenia and Osteporosis Prevention
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Low-Risk Pregnant Women at Full-Term Gestation
Healthy Fetal Population
Healthy Neonatal Population
Keywords: Bone mineral Density
Fetus
Newborns
Children
Osteoporosis
Environment
Oxidative stress
Endocrine disruptors
Lead sponsor: University of Parma
Sponsor class: OTHER
Collaborators: name: Azienda Ospedaliero-Universitaria di Parma
name: Azienda Ospedaliero Universitaria "Gaetano Martino" Messina
First posted: 2024-12-27
Enrollment: 200
Sex: ALL
Minimum age (years): 37
Maximum age (years): 42
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: All factors that influence the peak bone mass achieved at skeletal maturity are important in determining an individual's risk of developing osteoporosis later in life. Bone health begins with maternal health and nutrition, which influence skeletal mass and bone density in utero. The mechanisms underlying the effect of the intrauterine environment on bone health are currently unknown, but certainly include 'fetal programming' of oxidative stress and endocrine systems, as these influence skeletal growth and development later in life.

For the prevention of bone health, the challenges rely 1) in the need for new technology and software specific and applicable to the fetus and newborn; 2) in establishing the effect of environmental contaminants, in particular endocrine disruptors, oxidative stress and subsequent epigenetic changes in mothers and subsequently on the fetus, newborn and infant.

Detailed description: Maximising bone mass during skeletal growth has become the goal of primary prevention of osteopenia and osteoporosis. Any factor that might influence the peak bone mass attained during skeletal maturation is important in determining an individual's risk of developing osteoporosis later in life. Bone health begins with maternal health and nutrition, which influence skeletal mass and bone density in the foetus. The acquisition of peak bone mass is also genetically influenced by both parents. To date, there is some evidence that the risk of osteoporosis in later life may be determined by environmental exposures during intrauterine or early postnatal life. The mechanisms underlying the long-term effects of the intrauterine environment on bone health are currently unknown, but certainly include "fetal programming" of oxidative stress and endocrine systems that influence skeletal growth and development in utero and after birth.

Osteopenia is increasingly diagnosed in low birth weight infants. Intrauterine growth restriction (IUGR) further increases the risk of obesity and metabolic syndrome, conditions that significantly compromise bone quality. Recent studies have highlighted the central role of microRNAs (miRNAs) in bone growth and mineralisation, alongside peptides such as irisin and HMGB-1. These peptides are involved in glucose metabolism and the regulation of adipose and muscle tissue and have recently been linked to bone metabolism. MicroRNAs and long non-coding RNAs (lncRNAs) have gained attention for their ability to regulate gene expression post-transcriptionally, providing epigenetic modifications that influence growth plate and bone development. It remains unclear how maternal nutritional factors affect fetal bone mineral density (BMD) or how variations in fetal BMD may influence birth outcomes, such as spontaneous clavicle or skull fractures during operative delivery, and long-term bone mineralisation.

These findings highlight the importance of assessing skeletal status during the perinatal period. Early identification of conditions that affect bone mass or mineralisation and ongoing monitoring of bone development are essential to improve outcomes.

Radiofrequency echographic multi-spectrometry (REMS) technology has demonstrated its utility in the assessment of BMD in pregnant women. While few studies have investigated the use of transmission ultrasound to assess bone status in neonates, REMS technology shows great promise. Its advantages include the absence of ionising radiation, ease of use and, most importantly, the potential to conduct longitudinal studies of REMS patterns from the intrauterine period into the first year of life.

This innovative approach offers new opportunities to understand the maternal-fetal factors that influence bone health and to develop strategies to optimise bone development from the earliest stages of life.

The aims of the present study are A) To determine the feasibility of using REMS as a precise and innovative technology to assess the skeletal status of fetuses, neonates and children.

B) To assess how maternal REMS patterns and her anthropometric and gestational data influence REMS parameters in the fetus, newborn and during the first year of life.

C) To elucidate the relationships between early exposure to endocrine disrupters, oxidative stress and maternal diet as part of the in utero exposome and later body composition and bone health.

Eligibility criteria: Inclusion Criteria:

* term infants from low-risk pregnancy
* (37-42 weeks gestational age)
* Single pregnancy
* Absence of current or previous maternal diseases that could potentially interfere with bone metabolism (e.g., thyroid, kidney, liver disease)
* Absence of motor disability of the mother
* No previous history of recent, previous bone fractures or traumatic fractures (in the mother)
* No intake of vitamin D or other medications during pregnancy
* Maternal age \>18 years
* No diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)

Exclusion Criteria:

* preterm infants
* Infants hospitalized since birth for special conditions
* infants with metabolic disorders
* infants with genetic syndromes

Primary outcomes:
measure: Bone Mineral Density (BMD)
timeFrame: >37 and <42 weeks; 48 hours; 1, 3, 6, and 12 months
measure: MicroRNA assay on umbilical cord blood
timeFrame: at birth
measure: Endocrine disruptors (EDCs) on umbilical cord blood at birth.
timeFrame: at birth
measure: Endocrine disruptors (EDCs) on urine at 1 months of age.
timeFrame: 1 month
measure: Oxidative stress (OS) profile
timeFrame: at birth, 1 month
measure: Oxidative stress (OS) molecules
timeFrame: at birth, 1 month
measure: Lipid mediators involved in oxidative stress
timeFrame: at birth, 1 month
measure: Standard biochemical tests
timeFrame: at birth, 1 month
measure: Exposure to endocrine disruptors (EDCs) related to diet, clothing and the use of cosmetics and detergents.
timeFrame: at the enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Messina
country: Italy
facility: Azienda Ospedaliero Universitaria "Gaetano Martino" di Messina
state: ME
city: Parma
country: Italy
facility: Azienda Ospedaliero-Universitaria di Parma
Study officials:
References:
citation: Heaney RP. BMD: the problem. Osteoporos Int. 2005 Sep;16(9):1013-5. doi: 10.1007/s00198-005-1855-y. Epub 2005 Mar 18. No abstract available.
citation: Godfrey K, Walker-Bone K, Robinson S, Taylor P, Shore S, Wheeler T, Cooper C. Neonatal bone mass: influence of parental birthweight, maternal smoking, body composition, and activity during pregnancy. J Bone Miner Res. 2001 Sep;16(9):1694-703. doi: 10.1359/jbmr.2001.16.9.1694.
citation: Lanham SA, Roberts C, Perry MJ, Cooper C, Oreffo RO. Intrauterine programming of bone. Part 2: alteration of skeletal structure. Osteoporos Int. 2008 Feb;19(2):157-67. doi: 10.1007/s00198-007-0448-3. Epub 2007 Aug 18.
citation: Dirkes RK, Welly RJ, Mao J, Kinkade J, Vieira-Potter VJ, Rosenfeld CS, Bruzina PS. Gestational and lactational exposure to BPA, but not BPS, negatively impacts trabecular microarchitecture and cortical geometry in adult male offspring. Bone Rep. 2021 Nov 3;15:101147. doi: 10.1016/j.bonr.2021.101147. eCollection 2021 Dec.
citation: Papaioannou G. miRNAs in Bone Development. Curr Genomics. 2015 Dec;16(6):427-34. doi: 10.2174/1389202916666150817202425.
citation: Bocheva G, Boyadjieva N. Epigenetic regulation of fetal bone development and placental transfer of nutrients: progress for osteoporosis. Interdiscip Toxicol. 2011 Dec;4(4):167-72. doi: 10.2478/v10102-011-0026-6.
citation: Holroyd C, Harvey N, Dennison E, Cooper C. Epigenetic influences in the developmental origins of osteoporosis. Osteoporos Int. 2012 Feb;23(2):401-10. doi: 10.1007/s00198-011-1671-5. Epub 2011 Jun 9.
citation: Zhang L, Tang Y, Zhu X, Tu T, Sui L, Han Q, Yu L, Meng S, Zheng L, Valverde P, Tang J, Murray D, Zhou X, Drissi H, Dard MM, Tu Q, Chen J. Overexpression of MiR-335-5p Promotes Bone Formation and Regeneration in Mice. J Bone Miner Res. 2017 Dec;32(12):2466-2475. doi: 10.1002/jbmr.3230. Epub 2017 Aug 28.
citation: Perrone S, Santacroce A, Picardi A, Buonocore G. Fetal programming and early identification of newborns at high risk of free radical-mediated diseases. World J Clin Pediatr. 2016 May 8;5(2):172-81. doi: 10.5409/wjcp.v5.i2.172. eCollection 2016 May 8.
citation: Street ME, Bernasconi S. Endocrine-Disrupting Chemicals in Human Fetal Growth. Int J Mol Sci. 2020 Feb 20;21(4):1430. doi: 10.3390/ijms21041430.
citation: Predieri B, Alves CAD, Iughetti L. New insights on the effects of endocrine-disrupting chemicals on children. J Pediatr (Rio J). 2022 Mar-Apr;98 Suppl 1(Suppl 1):S73-S85. doi: 10.1016/j.jped.2021.11.003. Epub 2021 Dec 15.
citation: Degennaro VA, Brandi ML, Cagninelli G, Casciaro S, Ciardo D, Conversano F, Di Pasquo E, Gonnelli S, Lombardi FA, Pisani P, Ghi T. First assessment of bone mineral density in healthy pregnant women by means of Radiofrequency Echographic Multi Spectrometry (REMS) technology. Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:44-49. doi: 10.1016/j.ejogrb.2021.06.014. Epub 2021 Jun 15.
citation: Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun. 2001 Oct 19;288(1):275-9. doi: 10.1006/bbrc.2001.5747.
citation: Wang X, Liang T, Zhu Y, Qiu J, Qiu X, Lian C, Gao B, Peng Y, Liang A, Zhou H, Yang X, Liao Z, Li Y, Xu C, Su P, Huang D. Melatonin prevents bone destruction in mice with retinoic acid-induced osteoporosis. Mol Med. 2019 Aug 28;25(1):43. doi: 10.1186/s10020-019-0107-0.
citation: Perrone S, Laschi E, Buonocore G. Oxidative stress biomarkers in the perinatal period: Diagnostic and prognostic value. Semin Fetal Neonatal Med. 2020 Apr;25(2):101087. doi: 10.1016/j.siny.2020.101087. Epub 2020 Jan 23.